Past and upcoming special events for Isarna are listed here:

May 07, 2014: TGF-β - A Prime Target for Cancer Immunotherapy (CIMT Satellite Symposium)

Isarna Therapeutics sponsored a satellite symposium as part of the Association for Cancer Immunotherapy (CIMT) Annual Meeting in Mainz, Germany. The symposium brought together noted leaders in TGF-β to discuss the role of this important target for immunotherapy in oncology.

Dr. Michel Janicot, Isarna’s Head of Preclinical Research and Development, chaired the symposium that featured the following presentations:

  • General role for TGF-β in the immune system - Dr. Lalage Wakefield (National Cancer Institute, Bethesda, USA),
  • TGF-β signaling in cancer - Dr. Joan Seoane (Vall D’Hebron Institute of Oncology, Barcelona, Spain), and
  • Targeting TGF-β in cancer - Dr. Michael Weller (University Hospital Zurich, Switzerland)

Please click below to view a video of the symposium highlights:

Please click below to download the symposium booklet, which includes a short summary of TGF-beta’s role in the immune system by Dr. Wakefield of the NCI, all speaker presentations and speaker bios:

October 15, 2013: Opening of new Munich offices

To view a short video of the event including brief statements from Isarna CEO Dr. Philippe Calais; scientific advisor Prof. Dr. Michael Weller, University Hospital Zurich; and key investor, Dr. Matthias Kromayer, Vorstand MIG; please click below: